This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Lymphoma	Colony stimulating factor 1 receptor (CSF1R; C-FMS; CD115)	<p><i>In vitro</i> studies suggest that targeting long terminal repeat (LTR)-driven transcription of CSF1R could help treat Hodgkin's lymphoma. In Hodgkin's lymphoma cells, transcription of CSF1R required an activated LTR region in the promoter region of the <i>CSF1R</i> gene. Inhibitors of CSF1R transcription induced cell death in Hodgkin's lymphoma cell lines. In anaplastic large cell lymphoma, LTR-driven CSF1R transcription was also detected, suggesting the mechanism could be targeted in other lymphomas. Next steps include developing therapeutics that interfere with LTR-driven transcription to treat cancer and validating the association between LTR-driven transcription and lymphomas for diagnostic purposes.</p> <p>SciBX 3(19); doi:10.1038/scibx.2010.582 Published online May 13, 2010</p>	<p>Patent application filed covering LTR transcripts as targets and diagnostic tools for human cancers; patent application filed for use of CSF1R LTRs as therapeutic targets or sensitive biomarkers for Hodgkin's lymphoma; available for licensing for developing diagnostic assays or therapeutics based on the new targets</p>	<p>Lamprecht, B. <i>et al. Nat. Med.</i>; published online May 2, 2010; doi:10.1038/nm.2129 Contact: Stephan Mathas, Charité-University Hospital Berlin, Berlin, Germany e-mail: stephan.mathas@charite.de Contact: Constanze Bonifer, University of Leeds, St. James's University Hospital, Leeds, U.K. e-mail: c.bonifer@leeds.ac.uk</p>